Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology.

摘要: Silodosin determines smooth muscle relaxation in bladder and prostate tissues, increases blood flow conditions of chronic ischemia regulates the activity transcriptional factors responsible for stromal growth hyperplasia. Phase III trials have already demonstrated efficacy safety silodosin treatment patients bothered by lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). We aimed describe rationality use summarize current literature on LUTS. PubMed Web Science were queried with terms: ‘silodosin’ combination (AND) terms ‘lower symptoms’, ‘LUTS’, ‘pathophysiology’, ‘symptoms’ OR ‘therapy’. Studies published last 10 years (2007–2017) adults core clinical journals English included. 8 mg once-daily was superior placebo improving IPSS total score, voiding subscore, storage subscore QoL at least as effective tamsulosin 0.4 mg all analyses. In addition, studies assessing effect urodynamic parameters showed that determined a higher improvement outlet obstruction index compared other alpha1 adrenergic receptor antagonists. Concerning profile, long-term data (after 9 months treatment) confirmed limited cardiovascular gastrointestinal systems. Although ejaculatory disorders represented main complaint taking silodosin, discontinuation rate due this condition remained low even follow-up study (7.5%). Encouraging findings may be administered medical expulsive therapy promoting spontaneous stone passage distal ureteral stones < 10 mm, relieve LUTS who underwent cancer brachytherapy increase likelihood successful without catheter experiencing acute retention. is one drugs approved BPH, being highly not only but also parameter impairments BPH. Moreover, it has shown stones previous prospective randomized trials. Sponsorship article processing charges funded Recordati.